{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:12:41Z","timestamp":1790446361334,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.08.014","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:17:06Z","timestamp":1662592626000},"page":"28-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed\/Refractory Acute Myeloid Leukemia: A Single-Centre Experience"],"prefix":"10.1016","volume":"23","author":[{"given":"Anna","family":"Kopi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"W\u0119glarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Armatys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Spa\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Grygoruk-Wi\u015bniowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gromek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.08.014_bib0001","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.08.014_bib0002","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","article-title":"ELN with stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation","volume":"56","author":"Jentzsch","year":"2021","journal-title":"Bone Mar Transpl"},{"key":"10.1016\/j.clml.2022.08.014_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.08.014_bib0004","first-page":"184","volume":"4","author":"Hiddemann","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.014_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2018.11.016","article-title":"Efficacy and feasibility of allogeneic hematopoietic stem-cell transplantation in the treatment of refractory acute myeloid leukemia","volume":"19","author":"Ciftciler","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.08.014_bib0006","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine- based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0007","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapse and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.014_bib0008","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplantat in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.08.014_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjh.15077","article-title":"Treatment of relapse\/refractory acute myeloid leukemias in adults","volume":"181","author":"Rashidi","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.08.014_bib0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2018-99-111582","article-title":"Maintenance with 5-Azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients","volume":"132","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0011","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacytidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2022.08.014_bib0012","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT 3- internal tandem duplication mutation (SORMAIN)","volume":"10","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.08.014_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620719882666","article-title":"Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant","volume":"10","author":"Bazarbachi","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2022.08.014_bib0014","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults:2017 ENL recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0017","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0018","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.leu.2402753","article-title":"Summary: Reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection","volume":"17","author":"Lion","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.014_bib0019","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.08.014_bib0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.23655","article-title":"Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.08.014_bib0021","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","article-title":"Sequential allogeneic hematopoietic stem cell transplantation for acute refractory\/relapsed myeloid malignancies: results of reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC","volume":"99","author":"Bourgeois le","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.08.014_bib0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","article-title":"Comparison of match sibiling donors versus unrelated donors in allogeneic stem cell transplantation for primary refreactory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Brissot","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.08.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13548","article-title":"Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance","volume":"23","author":"Lindsay","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2022.08.014_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13440","article-title":"Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?","volume":"22","author":"Bueno","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2022.08.014_bib0025","article-title":"Re-examining the relationship between active cytomegalovirus (CMV) infection and acute graft-versus- host disease in allogeneic stem cell transplantation in era of real- time PCR CMV assays","volume":"29","author":"Gimenez","year":"2016","journal-title":"Transpl Inf"},{"key":"10.1016\/j.clml.2022.08.014_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2141.2001.02519.x","article-title":"Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukemia: the case for tailored graft-versus-host disease prophylaxis","volume":"112","author":"Craddock","year":"2001","journal-title":"B J Haematol"},{"key":"10.1016\/j.clml.2022.08.014_bib0027","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.08.014_bib0028","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/leu.2012.135","article-title":"Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation","volume":"26","author":"Baron","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.014_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41409-018-0221-6","article-title":"Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia","volume":"54","author":"Kato","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.08.014_bib0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long- term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.08.014_bib0031","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bmt.2017.8","article-title":"Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy","volume":"52","author":"Gyurkocza","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.08.014_bib0032","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced- intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"10","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.08.014_bib0033","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.08.014_bib0034","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacytidine and donor lymphocyte infusions \u2013 a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.08.014_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ejh.13628","article-title":"Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis","volume":"107","author":"Drozd-Soko\u0142owska","year":"2021","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022006231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022006231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:48Z","timestamp":1761871308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022006231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022006231"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed\/Refractory Acute Myeloid Leukemia: A Single-Centre Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}